mutLBSgeneDB |
Gene summary for NR2E1 |
Gene summary |
Basic gene Info. | Gene symbol | NR2E1 |
Gene name | nuclear receptor subfamily 2, group E, member 1 | |
Synonyms | TLL|TLX|XTLL | |
Cytomap | UCSC genome browser: 6q21 | |
Type of gene | protein-coding | |
RefGenes | NM_001286102.1, NM_003269.4, | |
Description | nuclear receptor TLXnuclear receptor subfamily 2 group E member 1protein tailless homologtailes-related receptortailless homolog | |
Modification date | 20141207 | |
dbXrefs | MIM : 603849 | |
HGNC : HGNC | ||
Ensembl : ENSG00000112333 | ||
HPRD : 07230 | ||
Vega : OTTHUMG00000015319 | ||
Protein | UniProt: Q9Y466 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_NR2E1 | |
BioGPS: 7101 | ||
Pathway | NCI Pathway Interaction Database: NR2E1 | |
KEGG: NR2E1 | ||
REACTOME: NR2E1 | ||
Pathway Commons: NR2E1 | ||
Context | iHOP: NR2E1 | |
ligand binding site mutation search in PubMed: NR2E1 | ||
UCL Cancer Institute: NR2E1 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID |
Top |
Ligand binding site mutations for NR2E1 |
Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.) : non-synonymous mutation on LBS, Circle size denotes number of samples. |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | Y380 | K381T | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for NR2E1 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | Y380 | K381T | -0.83639045 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for NR2E1 from PDB |
Top |
Differential gene expression and gene-gene network for NR2E1 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for NR2E1 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for NR2E1 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of NR2E1 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
Top |
Conservation information for LBS of NR2E1 |
Multiple alignments for Q9Y466 in multiple species |
LBS | AA sequence | # species | Species | A190 | VCESAARLLFM | 3 | Homo sapiens, Mus musculus, Gallus gallus | A190 | ITSKQIRTETI | 1 | Caenorhabditis elegans | C186 | ATESVCESAAR | 3 | Homo sapiens, Mus musculus, Gallus gallus | C186 | ETRAITSKQIR | 1 | Caenorhabditis elegans | E183 | YEVATESVCES | 3 | Homo sapiens, Mus musculus, Gallus gallus | E183 | HATETRAITSK | 1 | Caenorhabditis elegans | E187 | TESVCESAARL | 3 | Homo sapiens, Mus musculus, Gallus gallus | E187 | TRAITSKQIRT | 1 | Caenorhabditis elegans | F194 | AARLLFMSIKW | 3 | Homo sapiens, Mus musculus, Gallus gallus | F194 | QIRTETISGSS | 1 | Caenorhabditis elegans | F363 | IEEVFFKKTIG | 3 | Homo sapiens, Mus musculus, Gallus gallus | F363 | ASSPSSSRPRH | 1 | Caenorhabditis elegans | I372 | GNV-PITRLLS | 3 | Homo sapiens, Mus musculus, Gallus gallus | I372 | HSIRSITELLS | 1 | Caenorhabditis elegans | K365 | EVFFKKTIGNV | 3 | Homo sapiens, Mus musculus, Gallus gallus | K365 | SPSSSRPRHSI | 1 | Caenorhabditis elegans | L376 | PITRLLS---- | 3 | Homo sapiens, Mus musculus, Gallus gallus | L376 | SITELLSIQEE | 1 | Caenorhabditis elegans | R191 | CESAARLLFMS | 3 | Homo sapiens, Mus musculus, Gallus gallus | R191 | TSKQIRTETIS | 1 | Caenorhabditis elegans | S377 | ITRLLS----D | 3 | Homo sapiens, Mus musculus, Gallus gallus | S377 | ITELLSIQEEE | 1 | Caenorhabditis elegans | T366 | VFFKKTIGNV- | 3 | Homo sapiens, Mus musculus, Gallus gallus | T366 | PSSSRPRHSIR | 1 | Caenorhabditis elegans | Y380 | ---DMYKSSDI | 3 | Homo sapiens, Mus musculus, Gallus gallus | Y380 | QEEESVNVEEV | 1 | Caenorhabditis elegans |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |